#uptravi

Side effects.

- I feel very, very cold, freezing.

- my head hurts, my body hurts, my legs and arms hurts, my muscles hurts

- I feel like I have flu

Back home from the hospital. But lost only 4 kilograms of fluids. Furosemid straight to my veins, first infusion to my right arm held only for one day, then several attempts to get another infusion, led to my arm being now blue-green-purple from hematoms. So they had to create catheter in my neck. 

Doctor was so glad, that he can use old scars from catheterisation done in April, he used them as navigation to know, where to get tube to my body :-) Funny enough, on 17th December, I will have another catheterisation done at the same place! Yeah! So much fun! Catheter was badly covered, so nurses re-done it 6x times, therefore skin on my neck is now very very irritated. Try to have plaster get on and off for 6x times on the exact same place. Fantastic pain. 

Hospital was awful. I had to go to Ostrava instead of Olomouc and it was like prehistory versus 21st century. They restricted my food to low sodium diet of course, but no one was watching how much I drink and tea was re-filled twice a day. Logic? None. 

Legs aren´t so swollen and now I am still waiting for my insurance company to approve Uptravi, because Veletri (Flolan) isn´t working. Of course, Veletri is working for everyone except me. 7,5 months of wasted time on Veletri. And next Tuesday again to the hospital, to Olomouc, to change dressing of my catheter for infusion pump. 

For several days, 6 tubes were attached to my body. Not entertaining. And I had to go to toilet, to pee, to chair with a hole, so they can measure how much I pee.

And I had to get second infusion with potassium, because furosemid get potassium from my body out and hypokalemia is dangerous. 

New Post has been published on http://myway123.com/actelion-receives-canada-approval-for-uptravi/

Actelion receives Canada approval for Uptravi

A general view shows Swiss biotech group Actelion Headquarters in Allschwil near Basel February 17, 2015.

Reuters/Arnd Wiegmann

ZURICH Actelion Ltd (ATLN.VX), Europe’s biggest biotech firm, said on Tuesday that Health Canada had granted a notice of compliance for Uptravi, a new pulmonary arterial hypertension medicine.

The approval is “a major milestone”, Chief Executive Jean-Paul Clozel said in a statement, adding that the company is working to make the drug available to patients in Canada “as soon as possible”.

Analysts have said Uptravi could reap more than $ 1 billion in global sales annually at its peak.

(Reporting by Joshua Franklin; editing by Brenna Hughes Neghaiwi)

Investors worried about China’s plummeting currency are pouring money into assets overseas, and as Tara Joseph reports the flow of money is getting bigger just as authorities need investment back home.  Video 

Yuan speculator says China reserves could drop $ 200 billion in January

The Most Influential Scientific Minds

Using citation analysis to identify authors whose papers wield outsized influence

Global Innovation in 2015

The Year in Biopharma